Details

Autor(en) / Beteiligte

• Hoff, Leonardo Santos
• Ravichandran, Naveen
• Shinjo, Samuel Katsuyuki
• Day, Jessica
• Sen, Parikshit
• Junior, Jucier Gonçalves
• Lilleker, James B.
• Joshi, Mrudula
• Agarwal, Vishwesh
• Kardes, Sinan
• Kim, Minchul
• Milchert, Marcin
• Makol, Ashima
• Gheita, Tamer
• Salim, Babur
• Velikova, Tsvetelina
• Gracia-Ramos, Abraham Edgar
• Parodis, Ioannis
• O’Callaghan, Albert Selva
• Nikiphorou, Elena
• Tan, Ai Lyn
• Chatterjee, Tulika
• Cavagna, Lorenzo
• Saavedra, Miguel A.
• Ziade, Nelly
• Knitza, Johannes
• Kuwana, Masataka
• Nune, Arvind
• Distler, Oliver
• Cansu, Döndü Üsküdar
• Traboco, Lisa
• Wibowo, Suryo Angorro Kusumo
• Tehozol, Erick Adrian Zamora
• Serrano, Jorge Rojas
• La Torre, Ignacio García-De
• Wincup, Chris
• Pauling, John D.
• Chinoy, Hector
• Agarwal, Vikas
• Aggarwal, Rohit
• Gupta, Latika

Titel

COVID-19 severity and vaccine breakthrough infections in idiopathic inflammatory myopathies, other systemic autoimmune and inflammatory diseases, and healthy controls: a multicenter cross-sectional study from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) survey

Ist Teil von

• Rheumatology international, 2023-01, Vol.43 (1), p.47-58

Ort / Verlag

Berlin/Heidelberg: Springer Berlin Heidelberg

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• Objectives We aimed to compare the spectrum and severity of COVID-19 and vaccine breakthrough infections (BIs) among patients with IIMs, other systemic autoimmune and inflammatory diseases (SAIDs), and healthy controls (HCs). Methods This is a cross-sectional study with data from the COVAD study, a self-reported online global survey that collected demographics, COVID-19 history, and vaccination details from April to September 2021. Adult patients with at least one COVID-19 vaccine dose were included. BIs were defined as infections occurring > 2 weeks after any dose of vaccine. Characteristics associated with BI were analyzed with a multivariate regression analysis. Results Among 10,900 respondents [42 (30–55) years, 74%-females, 45%-Caucasians] HCs were (47%), SAIDs (42%) and IIMs (11%). Patients with IIMs reported fewer COVID-19 cases before vaccination (6.2%-IIM vs 10.5%-SAIDs vs 14.6%-HC; OR = 0.6, 95% CI 0.4–0.8, and OR = 0.3, 95% CI 0.2–0.5, respectively). BIs were uncommon (1.4%-IIM; 1.9%-SAIDs; 3.2%-HC) and occurred in 17 IIM patients, 13 of whom were on immunosuppressants, and 3(18%) required hospitalization. All-cause hospitalization was higher in patients with IIM compared to HCs [23 (30%) vs 59 (8%), OR = 2.5, 95% CI 1.2–5.1 before vaccination, and 3 (18%) vs 9 (5%), OR = 2.6, 95% CI 1.3–5.3 in BI]. In a multivariate regression analysis, age 30–60 years was associated with a lower odds of BI (OR = 0.7, 95% CI 0.5–1.0), while the use of immunosuppressants had a higher odds of BI (OR = 1.6, 95% CI 1.1–2.7). Conclusions Patients with IIMs reported fewer COVID-19 cases than HCs and other SAIDs, but had higher odds of all-cause hospitalization from COVID-19 than HCs. BIs were associated with the use of immunosuppressants and were uncommon in IIMs.